CD20-negative diffuse large B-cell lymphoma (DLBCL) is a rare and heterogeneous group of aggressive lymphoproliferative disorders. Described variants of CD20-negative DLBCL include plasmablastic lymphoma, primary effusion lymphoma, large B-cell lymphoma arising in HHV-8-associated multicentric Castleman ...
原发性CD20阴性的大B细胞淋巴瘤(De novo CD20-negative large B-cell lymphoma)。感谢埃默里大学医院副教授,血液病理学家,外科病理学主任Kyle Bradley, MD提供此病例学习。 De novo CD20-negative large B-cell lymphoma is rare. Most CD20(-) cases are p...
CD20-negative diffuse large B cell lymphoma: a comprehensive analysis of 695 cases. Tumour Biol. 2016; 37: 3619-3637.Li J, Zhao S, Wang J, Chen J, Wen W, Zhang Q. CD20-negative diffuse large B cell lymphoma: a comprehensive analysis of 695 cases. Tumour Biol. 2016;37(3):3619-...
Lymphoma Lymphoma. 2013; e290585.Gaur S, Padilla O, Nahleh Z (2013) Clinical features and prognosis of CD20 negative aggressive B-cell non-Hodgkins lymphoma. Lymphoma: 290585Sumit Gaur, Osvaldo Padilla, Zeina Nahleh. (2013) Clinical Features and Prognosis of CD20 Negative Aggressive B-Cell ...
【Abstract】CD20-negative diffuse large B-cell lymphoma is a rare and invasive type of lymphoproliferative disorders. Given the lack of CD20 expression, atypical cellular morphology and aggressive clinical behavior characterized by chemotherapy resistance and inferior survival rates. So CD20-negative DLBCL...
negative diffuse large B-cell lymphoma (DLBCL) is a rare and heterogeneous group of lymphoproliferative disorders.Given the lack of CD20 expression, atypical cellular morphology and aggressive clinical behavior characterized by chemotherapy resistance and inferior survival rates, CD20-negative DLBCL ...
[Relapse of diffuse large B cell lymphoma to CD20-negative multiple cutaneous tumors immediately after anti-CD20 monoclonal antibody (rituximab) therapy]. "Relapse of diffuse large B cell lymphoma to CD20-negative multiple cutaneous tumors immediately after anti-CD20 monoclonal antibody (rituximab) thera...
背景与目的:弥漫大B细淋巴瘤(diffuse large B cell lymphoma, DLBCL)是非霍奇金淋巴瘤(non-Hodgkin's lymphoma, NHL)最常见的亚型,是一组在临床表现,治疗疗效和远期预后等方面具有高度异质性的肿瘤.90%-95%的DLBCL表达B细胞特异抗原CD20.作为免疫靶向治疗药物利妥昔单抗(Rituximab,商品名美罗华)的治疗靶点,淋巴瘤...
原发纵隔 CD20 阴性弥漫大 B 细胞淋巴瘤1例并文献复习 The clinical data of one case of primary mediastinal CD20-negative diffuse large B-cell lymphoma were retrospectively analyzed, and the related literatures... 何海涛,王启,赵婕,... - 《Journal of Modern Medicine & Health》 被引量: 0发表:...
We studied 61 CD20- B-cell lymphomas, including 29 cases of precursor B-cell lymphoblastic leukemia/lymphoblastic lymphoma (B-ALL/B-LBL), 25 cases of CD20- recurrent mature B-cell lymphoma after rituximab therapy, and 7 cases of CD20- diffuse large B cell lymphoma (DLBCL). We used markers...